secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001104659-24-034239
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics reports FY2023 net loss $136.7M; cash $261.8M, runway into 2026
--------------------------------------------------------------------------------

- Net loss $136.7M in 2023 vs $131.0M in 2022; R&D expenses $92.7M, down from $97.2M.
- Cash, cash equivalents and investments $261.8M as of Dec 31, 2023; net cash used in ops $88.3M.
- Collaboration revenue from BMS agreement $2.2M in 2023, down from $5.2M in 2022.
- One-time impairment charge of $16.4M from consolidating facilities in Philadelphia and Seattle.
- FY2024 GAAP operating expense guidance $135M-$145M; cash runway expected into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/0001104659-24-034239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/tm248573d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-034239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer